Tradjenta | linagliptin 
Drug Class: DPP-4 Inhibitor
Manufacturer: Boerhinger Ingelheim
Approval Date: May 2011
What is Tradjenta and how does it work
Tradjenta is an oral drug that reduces blood sugar (glucose) levels in patients with type 2 diabetes by blocking the enzyme dipeptidyl peptidase-4 (DPP-4).
What is Tradjenta used for
Tradjenta is combined with diet and exercise to reduce blood glucose levels in individuals with type 2 diabetes.
How well does Tradjenta work
- Tradjenta reduced hemoglobin A1C by 0.4% compared to an increase of 0.3% for placebo after 24 weeks of treatment.
- Tradjenta reduced fasting glucose by 8.5 mg/dl compared to an increase of 14.8 mg/dl for placebo after 24 weeks of treatment.
- 25% of subjects that received Tradjenta achieved A1C less than 7% compared to 12% of subjects that received placebo for 24 weeks.
What are interesting facts about Tradjenta
- Only one dose strength
- Not eliminated by liver or kidneys
What is the dosage of Tradjenta and how is it administered
The recommended dose is 5 mg once daily orally.
What are the side effects of Tradjenta
Common: Stuffy or runny nose and sore throat
Serious: Pancreatitis, hypoglycemia when combined with sulfonylurea or insulin
Tradjenta drug interactions
Rifampin and other drugs that increase activity of liver enzymes that breakdown drugs reduce the concentration of Tradjenta in the body.
What is the cost of Tradjenta
Without insurance it may cost more than $6 per tablet.
How to obtain patient assistance for Tradjenta
References: Tradjenta Prescribing Information
The material on this site is for information only and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.
Comment on this article or post an article by joining the RxEconsult community.
Please Share on Your Social Networks
For More Healthcare Insights Join Us On Twitter and Facebook. Join The Community To Publish Articles.
Copyright 2023 RxEconsult. All Rights Reserved | Privacy Policy | Terms of Use | Sitemap